Update on clinical trials in the treatment of pulmonary disease in patients with cystic fibrosis

Bibliography

• ROMMENS JM, IANNUZZI MC, KEREM B et al: Identifica-tion of the cystic fibrosis gene: chromosome walking and jumping. Science (1989) 245:1059–1065.
   PubMed Web of Science ®Google Scholar
• RIORDAN JR, ROMMENS JM, KEREM B et al: Identifica-tion of the cystic fibrosis gene: cloning and characteri-sation of the complimentary DNA. Science (1989) 245:1066–1073.
   PubMed Web of Science ®Google Scholar
• KEREM BS, ROMMENS JM, BUCHANAN JA et al.: Identifi-cation of the cystic fibrosis gene: genetic analysis. Science (1989) 245:1073–1080.
   PubMed Web of Science ®Google Scholar
• GUGGINO WB: Cystic fibrosis and the salt controversy. Cell (1999) 96:607–610.
   PubMed Web of Science ®Google Scholar
• •An excellent synopsis of the two divergent models of the cystic fibrosis defect.
   Google Scholar
• MATSUI H GRUBB BR TARRAN R RANDELL SH GATZY JT DAVIS CW: Boucher RC. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell (1998) 95:1005–1015.
   Google Scholar
• ZABNER J. SMITH JJ KARP PH WIDDICOMBE JH WELSH MJ: Loss of CFTR chloride channels alters salt absorp-tion by cystic fibrosis airway epithelia in vitro. Mol. Cell (1998) 2:397–403.
   PubMed Web of Science ®Google Scholar
• GOLDMAN MJ, ANDERSON GM, STOLZENBERG ED, KARI UP, ZASLOFF M, WILSON JM: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 88:553–560.
   PubMed Web of Science ®Google Scholar
• ELBORN JS, SHALE DJ, BRITTON JR: Cystic fibrosis: current survival and population estimates to the year 2000. Thorax (1992) 46:881–885.
   Web of Science ®Google Scholar
• JOHNSON LG, OLSEN JC, SAKARADI B, MOORE KL, SWANSTROM R, BOUCHER RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nature Genet. (1992) 2:21–25.
   PubMed Web of Science ®Google Scholar
• STERN M, CAPLEN NJ, BROWNING JE et al.: The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther. (1998) 5:91–98.
   PubMed Web of Science ®Google Scholar
• ALTON EWFW, STERN M, FARLEY R et al.: Cationic lipid mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double blind placebo controlled trial. Lancet (1999) 353:947–954.
   PubMed Web of Science ®Google Scholar
• HOWARD M, FRIZELL R, BEDWELL D: Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. (1996) 2:467–469.
   PubMed Web of Science ®Google Scholar
• BEDWELL D, KAENJAK A, BENOS D et al.: Suppresion of a CFTR premature stop mutation in a bronchial epithe-lial cell line. Nature Med. (1997) 3:1280–1284.
   PubMed Web of Science ®Google Scholar
• BEDWELL DM, KAENJAK A, KEELING K et al.: Aminogly-coside repair of premature translation termination mutations. Pediatr. Pulmonol (1998) 17 (Suppl.):168.
   Google Scholar
• DENNING GM, ANDERSON MP, AMARA JF, MARSHALL J, SMITH AE, WELSH MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature sensitive. Nature (1992) 358:761–764.
   PubMed Web of Science ®Google Scholar
• SATO S, WARD CL, KROUSE ME, WINE JJ, KOPITO RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. (1996) 271:635–638.
   PubMed Web of Science ®Google Scholar
• JIANG C, FANG SL, XIAO et al.: Partial restoration of cAMP- stimulated CFTR chloride channel activity in deltaF508 cells by deoxyspergualin. Am. J. Physiol (1998) 275(1 pt1):C171–C178.
   Google Scholar
• RUBENSTEIN RC, ZEITLIN PL: In vitro pharmacological restoration of CFTR mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. (1997) 100:2457–2465.
   PubMed Web of Science ®Google Scholar
• ZEITLIN PL, RUBENSTEIN RC, BOYLE MP, CHU S: Phenyl-butyrate therapy for cystic fibrosis: basic mechanisms and clinical applications. Pediatr. Pulmonol (1998) 17 (Suppl.):164–166.
   Google Scholar
• RUBENSTEIN RC, ZEITLIN PL: A pilot clinical trial of sodium 4-phenylbutyrate (Bupheny0 in deltaF508 homozygous cystic fibrosis patients. Partial restora-tion of nasal epithelial CFTR function. Am. J. Respir. Grit. Care Med. (1998) 157:484–490.
   Google Scholar
• EIDELMAN 0, GUAY-BRODER C, VANGALEN PJM et al.:Ai-adenosine receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl. Acad. Sci. USA (1992) 89:5562–5566.
   Google Scholar
• POLLARD H, EIDELMAN 0, RAZIN M, FOSSMANN L, SRIVASTAVA M, ARISPE N CPX: Activation of CFTR channels and repair of AF508-CFTR trafficking defect. Pediatr. Pulmonol (1998) 17 (Suppl.):163–164.
   Google Scholar
• COHEN BE, LEE G, JACOBSON KA et al.: 8-cyclopenty1-1,3-dipropylxanthine and other xanthines differen-tially bind to the wild type and delta F508 first nucleo-tide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry (1997) 36:6455–6461.
   PubMed Web of Science ®Google Scholar
• ARISPE N, ROJAS E, HARTMAN J, SORSCHER EJ, POLLARD HB: Intrinsic anion channel activity of the recombi-nant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein. Proc. Natl. Acad. Sci. USA (1992) 89:1539–1543.
   PubMed Web of Science ®Google Scholar
• BECQ F JENSEN TJ CHANG XB et al.: Phosphatase inhibi-tors activate normal and defective CFTR chloride channels. Proc. Natl. Acad. Sci. USA (1994) 91:9160–9164.
   PubMed Web of Science ®Google Scholar
• KELLY TJ, THOMAS K, MILGRAM LJ, DRUMM ML: In vivoactivation of the cystic fibrosis transmembrane conductance regulator mutant AF508 in murine nasal epithelium. Proc. Natl. Acad. Sci. USA (1997) 94:2604–2608.
   PubMed Web of Science ®Google Scholar
• DRUMM ML, STEAGALL WK, KELLY TJ, MILGRAM LJH, KONSTAN M: Phosphodiesterase inhibitor stimulates chloride secretion from gut and respiratory epithelia. Pediatr. Pulmonol (1998) 17 (Suppl.) :168–169.
   Google Scholar
• HWANG TC, WANG F, AL-NAKKASH L, HU S: Pharma-cological modulation of wild type and mutant CFTR. Pediatr. Pulmonol. (1998) 17 (Suppl.) :167.
   Google Scholar
• KNOWLES MR, CHURCH NL, WALTNER WE et al.: A pilotstudy of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl. J. Med. (1990) 322:1189–1194.
   PubMed Web of Science ®Google Scholar
• APP EM, KING M, HILFESMEDER R, KOHLER D, MATTHYSH: Acute and long term amiloride inhalation in cystic fibrosis lung disease. Am. Rev. Respir. Dis. (1990) 141 :605–612.
   PubMed Web of Science ®Google Scholar
• GRAHAM A, HASANI A, ALTON EWFW et al: No addedbenefit from nebulised amiloride in patients with cystic fibrosis. Eur. Respk. J. (1993) 6:1243–1248.
   PubMed Web of Science ®Google Scholar
• HOFFMANN T, STUTTS MJ, ZIERSCH A et al: Effects oftopically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis. Am. J. Respir. Crit. Care Med. (1998) 157:1844–1849.
   PubMed Web of Science ®Google Scholar
• RODGERS HC, KNOX AJ: Randomized controlled crossover study of the effect of topically applied benzamil, amiloride or saline on nasal potential differ-ence in cystic fibrosis. Thorax (1998) 53:A19.
   Google Scholar
• KNOWLES MR, OLIVIER KN, HOHNEKER K, NOONE P, MASON S, BOUCHER RC: Acute safety and effect of aerosolised uridine 5'-triphosphate +/- amiloride. Pediatr. Pulmonol. (1993) 9(Suppl.):148–149.
   Google Scholar
• BENNETT WD, OLIVIER KN, ZEMAN KL, HOHNEKER KW,BOUCHER RC, KNOWLES MR: Effects of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am. J. Respir. Crit. Care Med. (1996) 153:1796–1801.
   PubMed Web of Science ®Google Scholar
• DOUGHERTY DW, CROOM DK, JAMES MK: Effects of INS365, A P2y2 receptor agonist, on components of the mucociliary clearance system. Pediatr. Pulmonol. (1998) 17 (Suppl.) :281.
   Google Scholar
• ZEITLIN PL, GUGGINO WB, MOLINA L: Activation by thenondecapeptide 2622490 (Duramycin) of chloride secretion in healthy volunteers and patients with cystic fibrosis. Pediatr. Pulmonol. (1998) 17(Suppl.):277–278.
   Google Scholar
• SHAH PL, SCOTT SF, KNIGHT RA, MARRIOTT C, RANASINHA C, HODSON ME: The in vivo effects of recombinant human DNase I on sputum in cystic fibrosis. Thorax (1996) 51:119–125.
   PubMed Web of Science ®Google Scholar
• HODSON ME, SHAH PL: DNase trials in cystic fibrosis.Eur. Respir. J. (1995) 8: 1786-1791.
   Google Scholar
• VASCONCELLOS CA, ALLEN PG, WOHL ME, DRAZEN JM,JANMEY PA, STOSSEL TP: Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science (1994) 263:969–971.
   PubMed Web of Science ®Google Scholar
• TULLIS DE, COREY M, DABORA R, SCARAMUCCI J, MAGILAVI D: A double-blind placebo controlled, dose escalating, tolerability study of inhaled recombinant gelsolin in cystic fibrosis. Pediatr. Pulmonol. (1998) 17 (Suppl.):275.
   Google Scholar
• APP EM, BARAN D, TOMKIEWICZ RP et al.: A pilot study of an aerosolised new mucolytic agent Nacystelyn® (NAL) for the treatment of lung disease and cystic fibrosis. Am. J. Respir. Crit. Care Med. (1994) 149:A676.
   Google Scholar
• APP EM, BARAN D, DAB I et al.: Efficacy, safety and tolerability of chronic inhalation therapy with Nacystelyn® versus placebo in cystic fibrosis patients. Am. J. Respir. Critic. Care Med. (1997) 155:A199.
   PubMedGoogle Scholar
• GHIO AJ, MARSHALL BC, DIAZ JL et al: Tyloxapol inhibits NFKB and cytokine release, scavenges HOC1 and reduces viscosity of cystic fibrosis sputum. Am. J. Respir. Critic. Care Med. (1995) 154:783–788.
   Web of Science ®Google Scholar
• MARSHALL BC, SAMUELSON WM, HOIDAL JR, HENSHAW C, CROCKFORD D, KENNEDY TP: Phase I studies of aerosolised tyloxapol in young, healthy adults. Pediatr. Pulmonol (1998) 17 (Suppl.):340.
   Google Scholar
• RUBIN BK, RAMIREZ OE, SMITH E, BARRETT J: Early results of clinical trials of Exosure for the therapy of cystic fibrosis lung disease. Pediatr. Pulmonol (1995) 12 (Suppl.):234.
   Google Scholar
• ROBINSON M, HEMMING AL, REGNIS JA et al: Effect ofincreasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax (1997) 52:900–903.
   PubMed Web of Science ®Google Scholar
• ENG PA, MORTON J, DOUGLASS JA, RIEDLER J, WILSON J, ROBERTSON CF: Short-term efficacy of ultrasonically nebulised hypertonic saline in cystic fibrosis. Pediatr. Pulmonol (1996) 21:77–83.
   PubMed Web of Science ®Google Scholar
• BALLMANN M, VON DER HARDT H: Hypertonic saline and recombinant human DNase: A randomized cross over pilot study in patients with cystic fibrosis. Pediatr. Pulmonol (1998) 17 (Suppl.):343.
   Google Scholar
• WEI F, GARRETT H, SPEERT DP, KING M: Improved clearability of cystic fibrosis sputum with dextran in vitro. Am. J. Respir Crit. Care Med. (1998) 157:710–714.
   PubMed Web of Science ®Google Scholar
• ROBINSON M, DAVISKAS E, EBERL S, BAKER J, ANDERSON SD, BYE PT: Effect of inhaling a dry powder of mannitol on mucociliary clearance in adults with cystic fibrosis. Pediatr. Pulmonol. (1998) 17(Suppl.):280.
   Google Scholar
• RAMSEY BW, PEPE MS, QUAN JM et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N.Engl. J. Med. (1999) 340:23–30.
   PubMed Web of Science ®Google Scholar
• HANCOCK REW: Cationic antimicrobial peptides as a potential lung infection therapy in cystic fibrosis. Pediatr. Pulmonol (1998) Suppl. 17:188.
   Google Scholar
• SCHWAB U, GILIGAN P, JAYNES J, HENKE D: Antipseudo-monal activity of peptidyl membrane interactive molecules (Peptidyl MIMSTI is salt independent. Pediatr. Pulmonol (1998) 17 (Suppl.):385.
   Google Scholar
• BARGHAUTI S, GUERDAUD LM, SPEERT DM: Inhibitionby dextran of P. aeruginosa adherence to epithelial cells. Am. J. Respir. Crit. Care Med. (1996) 154:1788–1793.
   PubMedGoogle Scholar
• KONSTAN MW, BYARD PJ, HOPPEL CL, DAVIS PB: Effectof high dose ibuprofen in patients with cystic fibrosis. N Engl. J. Med. (1995) 332:848–854.
   PubMed Web of Science ®Google Scholar
• ARONOFF SC, QUINN FJ JR, CARPENTER LS, NOVICH WJ, JR.: Effects of pentoxifylline on sputum neutrophil elastase and pulmonary function in patients with cystic fibrosis: preliminary observations. J. Pediatr. (1994) 125:992–997.
   Google Scholar
• SHAH PL, SCOTT SF, KNIGHT RA, HODSON ME: The effect of recombinant human DNase I on neutrophil elastase activity and interleukin-8 levels in cystic fibrosis. Eur. Respir. J. (1996) 9:531–534.
   PubMed Web of Science ®Google Scholar
• MCELVANEY NG, HUBBARD RC, BIRRER P et al.: Aerosol al-antitrypsin treatment for cystic fibrosis. Lancet (1991) 37:392–394.
   Web of Science ®Google Scholar
• BERGER M, KONSTAN M, HILLIARD J, CF PROLASTIN STUDY GROUP: Aerosolised Prolastin (1-protease inhibitor) in CF. Pediatr. Pulmonol (1995) 20:421.
   Google Scholar
• JACOBS FA, MANNES GP, HIEMSTRA PS, SCHOLS AM, BUURMAN NA, HEIJERMAN HG: Effect of inhaled FK706 on inflammatory mediators of pulmonary disease in adult patients with CF. Pediatr. PulmonoL (1998) 17 (Suppl.):375.
   Google Scholar
• VENDER RL, BURCHAM DL, QUON CY: DMP777: a synthetic neutrophil elastase inhibitor at therapy for cystic fibrosis. Pediatr. Pulmonol. (1998) 17 (Suppl.):136–137.
   Google Scholar